Two Natural Cap

Two Natural Cap

Home
Archive
About
UniQure: (Hopefully) Progress on miRNA Therapeutics $qure
siRNA vs miRNA, the FDA, Exon 1 vs Allele-Specific
Nov 6 • Two Natural Capital
Capstan Therapeutics: LNP Delivery Beyond the Liver $abbv
In-vivo CAR-T, Targeted LNPs, and Autoimmune Disease
Oct 7 • Two Natural Capital
MaxCyte: Powering Ex-Vivo Gene Editing $mxct
Casgevy, Allogeneic CAR-T, and Electroporation Technology
Sep 4 • Two Natural Capital
Maravai: Can an mRNA Capping Provider Move Beyond Covid? $mrvi
mRNA, Biologics Safety Testing, and Cell/Gene Therapy
Jul 25 • Two Natural Capital
CAR-T Therapy: How Can CRISPR Help?
Donors Cells, Immune System Evasion, AvenCell/Intellia/CRISPR Therapeutics
Jun 25 • Two Natural Capital
CRISPR Comes Back to Life
Baby KJ, LNPs, and Danaher
Jun 11 • Two Natural Capital
Casey’s General Stores: A Dollar General Approach to Gas Stations $casy
Pizza, Buc-ee’s, Expansion, and Zyn
May 7 • Two Natural Capital
In Situ Sequencing: 10x Genomics, NanoString, and Vizgen $txg $brkr
Lawsuits, Sensitivity/Specificity, and Mouse Brains
Apr 25 • Two Natural Capital
Two Natural Cap
Two Natural Cap
Writing about markets and life sciences; readers include investors from Baillie Gifford, GIC, and Susquehanna.
Recommendations
Owl Posting
Owl Posting
Abhishaike Mahajan
Net Interest
Net Interest
Marc Rubinstein
White Noise
White Noise
Tom White
Rough Diamonds
Rough Diamonds
Sarah Constantin
Base by Base
Base by Base
Edward Larkin

Two Natural Cap

AboutArchiveRecommendationsSitemap
© 2025 Two Natural Capital · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture